BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network. The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.
BioNTech said its expansion plans were supported by the Singapore Economic Development Board and would increase the global supply of mRNA-based vaccines and establish a production facility in southeast Asia to respond rapidly to future pandemics.

• China Increases Visa-Free Transit Stay to 10 Days
• India’s Gold Imports Set to Drop in December After Record November
• Mansukh Mandaviya Launches ‘Fit India Cycling Drive’ to Promote Fitness
• OpenAI Launches ChatGPT-Powered Search
• Dam Capital Advisors IPO: Lot Size, GMP, Key Dates and Company’s Insight

“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said Ugur Sahin, CEO and Co-founder of BioNTech. Governments around the world are looking to build up local vaccine production to secure access to supplies after manufacturing setbacks have slowed the rollout of Covid-19 doses in some countries.